In connection with the License Agreement, Windward Bio announced a US$200 million Series A financing round led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities with the co-investment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback